Thrombin generation in FXI-deficient plasma with inhibitors: ex vivo spiking with increasing concentrations of rFVIIa. This representative figure shows TGAs performed in our laboratory in the presence of FXI-deficient plasma (and FXI inhibitor) as compared with normal plasma. Ex vivo spiking with increasing concentrations of rFVIIa only slightly improved TGA parameters in FXI-deficient plasma. These experiments support the use of low-dose rFVIIa for the treatment of patients with FXI deficiency in order to mitigate thrombotic risks (for more details, refer to Livnat et al⁸¹).